{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T05:26:28Z","timestamp":1794547588211,"version":"4.9.1"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T00:00:00Z","timestamp":1755820800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.eclinm.2025.103494","type":"journal-article","created":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T23:31:12Z","timestamp":1759707072000},"page":"103494","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Neoadjuvant FLOT versus SOX chemotherapy in locally advanced gastric cancer: secondary outcomes of a single-centre, open-label, randomised, exploratory phase 2 trial"],"prefix":"10.1016","volume":"88","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7415-960X","authenticated-orcid":false,"given":"Birendra Kumar","family":"Sah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenjia","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benyan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenglun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wentao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenggang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eclinm.2025.103494_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.eclinm.2025.103494_bib2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa055531","article-title":"Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer","volume":"355","author":"Cunningham","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2025.103494_bib3","article-title":"Perioperative chemo(radio)therapy versus primary surgery for resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus","volume":"2013","author":"Ronellenfitsch","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.eclinm.2025.103494_bib4","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1200\/JCO.2010.33.0597","article-title":"Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial","volume":"29","author":"Ychou","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eclinm.2025.103494_bib5","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0140-6736(11)61873-4","article-title":"Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial","volume":"379","author":"Bang","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.eclinm.2025.103494_bib6","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1016\/S1470-2045(16)30531-9","volume":"17","author":"Al-Batran","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eclinm.2025.103494_bib7","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","volume":"393","author":"Al-Batran","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.eclinm.2025.103494_bib8","first-page":"CD004064","article-title":"Chemotherapy for advanced gastric cancer","volume":"8","author":"Wagner","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.eclinm.2025.103494_bib9","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0140-6736(20)31288-5","article-title":"Gastric cancer","volume":"396","author":"Smyth","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.eclinm.2025.103494_bib10","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S1470-2045(24)00676-4","volume":"26","author":"Zhang","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eclinm.2025.103494_bib11","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13045-024-01536-7","article-title":"Perioperative versus adjuvant S-1 plus oxaliplatin chemotherapy for stage II\/III resectable gastric cancer (RESONANCE): a randomized, open-label, phase 3 trial","volume":"17","author":"Wang","year":"2024","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.eclinm.2025.103494_bib12","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/annonc\/mdu472","article-title":"Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-na\u00efve patients with advanced gastric cancer","volume":"26","author":"Yamada","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eclinm.2025.103494_bib13","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1200\/JCO.24.00795","article-title":"Pathologic response of phase III study: perioperative camrelizumab plus rivoceranib and chemotherapy versus chemotherapy for locally advanced gastric cancer (DRAGON IV\/CAP 05)","volume":"43","author":"Li","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eclinm.2025.103494_bib14","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/cac2.12516","article-title":"The Chinese society of clinical oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023","volume":"44","author":"Wang","year":"2024","journal-title":"Cancer Commun"},{"key":"10.1016\/j.eclinm.2025.103494_bib15","first-page":"1","article-title":"Japanese gastric cancer treatment guidelines 2021 (6th edition)","volume":"26","year":"2023","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.eclinm.2025.103494_bib16","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s13045-025-01698-y","article-title":"The current landscape of gastric cancer and gastroesophageal junction cancer diagnosis and treatment in China: a comprehensive nationwide cohort analysis","volume":"18","author":"Chen","year":"2025","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.eclinm.2025.103494_bib17","doi-asserted-by":"crossref","first-page":"6093","DOI":"10.1038\/s41467-020-19965-6","article-title":"Neoadjuvant FLOT versus SOX phase II randomized clinical trial for patients with locally advanced gastric cancer","volume":"11","author":"Sah","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.eclinm.2025.103494_bib18","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1002\/cncr.11660","article-title":"Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy","volume":"98","author":"Becker","year":"2003","journal-title":"Cancer"},{"issue":"14","key":"10.1016\/j.eclinm.2025.103494_bib19","doi-asserted-by":"crossref","first-page":"3662","DOI":"10.3390\/cancers15143662","article-title":"Interpretation of tumor response grade following preoperative therapy for gastric cancer: an overview","volume":"15","author":"Tsagkalidis","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.eclinm.2025.103494_bib20","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/apm.1965.64.1.31","article-title":"The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification","volume":"64","author":"Lauren","year":"1965","journal-title":"Acta Pathol Microbiol Scand"},{"key":"10.1016\/j.eclinm.2025.103494_bib21","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.1002\/1097-0142(19940601)73:11<2680::AID-CNCR2820731105>3.0.CO;2-C","article-title":"Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations","volume":"73","author":"Mandard","year":"1994","journal-title":"Cancer"},{"key":"10.1016\/j.eclinm.2025.103494_bib22","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1200\/JCO.2011.39.1953","article-title":"Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial","volume":"30","author":"Lee","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eclinm.2025.103494_bib23","first-page":"264","article-title":"Current treatment and recent progress in gastric cancer","volume":"71","author":"Joshi","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.eclinm.2025.103494_bib24","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa2004413","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer","volume":"382","author":"Shitara","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2025.103494_bib25","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/S0140-6736(17)31827-5","article-title":"Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Kang","year":"2017","journal-title":"Lancet"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537025004274?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537025004274?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T05:06:23Z","timestamp":1794546383000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537025004274"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":25,"alternative-id":["S2589537025004274"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2025.103494","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neoadjuvant FLOT versus SOX chemotherapy in locally advanced gastric cancer: secondary outcomes of a single-centre, open-label, randomised, exploratory phase 2 trial","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2025.103494","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103494"}}